Figure 1.

IHC profiling of samples under study. A, IHC patterns at baseline TURBT compared with cystectomy (CYST). PDL1 staining was assessed as the CPS but also in tumor cells (tumor) and immune cells separately (noted as “PDL1 tumor” and “PDL1 immune,” respectively). Mann–Whitney U test. B, Comparison of the median CPS between tumors with a squamous component (SCC) and pure urothelial cancers (Mann–Whitney U test) and sectorial graph depicting the response to treatment (blue: pCR; orange: progressive disease). Numbers represent the CPS. C, Percentage of patients who achieved a clinical response (green bars) vs. those who did not (red bars), classified by the positive or negative expression of different IHC markers in the baseline (TURBT) sample [PDL1, PDL1 in tumor cells, PDL1 in immune cells, FAP, CD8, CD4, FOXP3, and granzyme B (GZMB); Fisher t test]. NR, nonresponder; R, responder. Degrees of statistical significance: ns, nonsignificant; *, P < 0.05; **, P < 0.01.